BR112022003670A2 - Métodos de tratamento - Google Patents
Métodos de tratamentoInfo
- Publication number
- BR112022003670A2 BR112022003670A2 BR112022003670A BR112022003670A BR112022003670A2 BR 112022003670 A2 BR112022003670 A2 BR 112022003670A2 BR 112022003670 A BR112022003670 A BR 112022003670A BR 112022003670 A BR112022003670 A BR 112022003670A BR 112022003670 A2 BR112022003670 A2 BR 112022003670A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- treatment methods
- tumors
- pde1
- certain cancers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895476P | 2019-09-03 | 2019-09-03 | |
| PCT/US2020/049248 WO2021046250A1 (en) | 2019-09-03 | 2020-09-03 | Methods of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003670A2 true BR112022003670A2 (pt) | 2022-05-24 |
Family
ID=74853030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003670A BR112022003670A2 (pt) | 2019-09-03 | 2020-09-03 | Métodos de tratamento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12599603B2 (https=) |
| EP (1) | EP4025218A4 (https=) |
| JP (1) | JP7631319B2 (https=) |
| KR (1) | KR20220054853A (https=) |
| CN (1) | CN114340636A (https=) |
| AU (1) | AU2020343329C1 (https=) |
| BR (1) | BR112022003670A2 (https=) |
| CA (1) | CA3147071A1 (https=) |
| IL (1) | IL290983A (https=) |
| MX (1) | MX2022002607A (https=) |
| WO (1) | WO2021046250A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020146384A1 (en) | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20220054853A (ko) | 2019-09-03 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치료 방법 |
| MX2024010993A (es) * | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690935A (en) | 1983-03-31 | 1987-09-01 | Wayne State University | Inhibition of tumor growth and metastasis with calcium channel blocker compounds |
| AU2006255028B2 (en) | 2005-06-06 | 2012-04-19 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20120012831A (ko) | 2007-12-06 | 2012-02-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| KR20110103949A (ko) | 2008-12-06 | 2011-09-21 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| MA32942B1 (fr) * | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
| US10695431B2 (en) | 2010-10-29 | 2020-06-30 | Infirst Healthcare Limited | Solid solution compositions and use in cardiovascular disease |
| WO2012177263A1 (en) | 2011-06-24 | 2012-12-27 | Intra-Cellular Therapies, Inc. | Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists |
| JP6224597B2 (ja) | 2011-09-27 | 2017-11-01 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | グリオーマを処置するための組成物及び方法 |
| WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| CA2877146C (en) | 2012-06-18 | 2020-10-20 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
| KR102240326B1 (ko) | 2013-03-15 | 2021-04-13 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| EP3157926B1 (en) | 2014-06-20 | 2019-05-15 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10131671B2 (en) * | 2014-08-07 | 2018-11-20 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2961212C (en) | 2014-09-17 | 2024-02-06 | Intra-Cellular Therapies, Inc. | Compounds and methods |
| US10849862B2 (en) * | 2014-12-26 | 2020-12-01 | Theravalues Corporation | Formulation of curcumin and anti-PD-1 antibody |
| JP2018515474A (ja) | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| CA2991628C (en) | 2015-07-16 | 2020-04-07 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| KR20180105685A (ko) * | 2016-02-08 | 2018-09-28 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 투카레솔 또는 이의 유사체를 함유하는 조성물 |
| JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| WO2018093591A1 (en) | 2016-11-03 | 2018-05-24 | Juno Therapeutics, Inc. | Combination therapy of a cell based therapy and a microglia inhibitor |
| EP3558319A4 (en) | 2016-12-22 | 2020-07-22 | AbbVie Inc. | COMPOSITIONS AND PROCESSES FOR IMPROVING OR INCREASING THE PRODUCTION OF TYPE I IFN |
| EP3612839A1 (en) | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy |
| TW201920104A (zh) | 2017-08-31 | 2019-06-01 | 美商馬愈法瑪公司 | 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途 |
| US20210338679A1 (en) | 2018-09-25 | 2021-11-04 | Intra-Cellular Therapies, Inc. | Novel uses |
| WO2020146384A1 (en) * | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20220054853A (ko) | 2019-09-03 | 2022-05-03 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치료 방법 |
| MX2024010993A (es) | 2022-03-11 | 2024-09-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
-
2020
- 2020-09-03 KR KR1020227010604A patent/KR20220054853A/ko active Pending
- 2020-09-03 US US17/640,050 patent/US12599603B2/en active Active
- 2020-09-03 AU AU2020343329A patent/AU2020343329C1/en active Active
- 2020-09-03 CN CN202080062144.3A patent/CN114340636A/zh active Pending
- 2020-09-03 MX MX2022002607A patent/MX2022002607A/es unknown
- 2020-09-03 WO PCT/US2020/049248 patent/WO2021046250A1/en not_active Ceased
- 2020-09-03 CA CA3147071A patent/CA3147071A1/en active Pending
- 2020-09-03 JP JP2022514215A patent/JP7631319B2/ja active Active
- 2020-09-03 EP EP20860677.2A patent/EP4025218A4/en active Pending
- 2020-09-03 BR BR112022003670A patent/BR112022003670A2/pt unknown
-
2022
- 2022-02-28 IL IL290983A patent/IL290983A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290983A (en) | 2022-05-01 |
| WO2021046250A1 (en) | 2021-03-11 |
| AU2020343329C1 (en) | 2026-02-12 |
| JP2022546711A (ja) | 2022-11-07 |
| JP7631319B2 (ja) | 2025-02-18 |
| AU2020343329A1 (en) | 2022-03-24 |
| US20220354851A1 (en) | 2022-11-10 |
| EP4025218A1 (en) | 2022-07-13 |
| MX2022002607A (es) | 2022-03-25 |
| KR20220054853A (ko) | 2022-05-03 |
| CN114340636A (zh) | 2022-04-12 |
| CA3147071A1 (en) | 2021-03-11 |
| US12599603B2 (en) | 2026-04-14 |
| AU2020343329B2 (en) | 2025-07-24 |
| EP4025218A4 (en) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| ZA202501583B (en) | Compounds and methods for the targeted degradation of androgen receptor | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2023005804A (es) | Piridazinonas como inhibidoras de poli(adenosin difosfato-ribosa) polimerasa 7 (parp7). | |
| MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| MX2019013858A (es) | Inhibidores de kras g12c y metodos para su uso. | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| CY1125116T1 (el) | Ενας αναστολεας βτκ για χρηση στη θεραπεια του καρκινου | |
| JOP20190154B1 (ar) | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم | |
| ZA201904652B (en) | Combinations of cabozantinib and atezolizumab to treat cancer | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| MX2024000253A (es) | Inhibicion del smarca2 para el tratamiento del cancer. | |
| MX2018008426A (es) | Combinaciones anti-egfr para tratar tumores. | |
| BR112019017403A2 (pt) | composições e métodos para o tratamento de câncer | |
| AU2018265888A1 (en) | Use of anti-B7H3 antibodies for treating cancer in the central nervous system | |
| MX374924B (es) | Terapia de combinacion con inhibidores de glutaminasa. | |
| CR20220156A (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
| EA202191257A1 (ru) | Противораковая терапия на основе иммуноцитов, связывающих liv1 | |
| BR112022003670A2 (pt) | Métodos de tratamento | |
| PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| MX2021009514A (es) | Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon. | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |